Atopix Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis
News Nov 19, 2013
Atopix Therapeutics Ltd has announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).
OC459 is designed as a once daily oral treatment. The first patient in this randomized, double-blind, placebo-controlled study was dosed at the University of Sheffield Medical Centre, United Kingdom.
The clinical study is funded by a grant from the Biomedical Catalyst fund and incorporates other leading dermatology centres in the UK, Germany, Austria, France and Finland which will initiate dosing shortly.
The study aims to detect an effect of OC459 on flares, the major health economic burden in atopic dermatitis. The primary endpoint of the study will be judged against the Eczema Activity Severity Index (EASI), a score which measures the extent and severity of atopic dermatitis.
Genetic variants in CRTH2 predispose patients to the development of atopic dermatitis. As a CRTH2 antagonist, OC459 has demonstrated in pre-clinical studies that it suppresses the recruitment and production of key cells that mediate an allergic response such as Th2 lymphocytes, basophils and eosinophils, resulting in reduced disease pathology.
It is anticipated that patients with a highly atopic Th2 dominant form of eczema, who typically have a more severe form of the disease and are prone to flares, will benefit from treatment with OC459.
Mark Payton, CEO of Atopix, said: “Recruitment of the first patient to this study is a key milestone in the development of OC459 for the treatment of moderate to severe atopic dermatitis. Our partnership with some of the leading dermatology investigators in the European Union demonstrates our shared belief that the suppression of Th2-mediated allergic responses following dosing with OC459 will benefit patients with this severe allergic disease. With approximately 3.2% of the US and EU population and 15-20% of children affected by atopic dermatitis, new treatments to effectively control the debilitating symptoms and intervene in disease progression are urgently required.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018